Tezepelumab normalizes serum interleukin-5 and -13 levels in patients with severe, uncontrolled asthma

Ann Allergy Asthma Immunol. 2021 Dec;127(6):689-691. doi: 10.1016/j.anai.2021.08.008. Epub 2021 Aug 14.
No abstract available

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Asthma* / drug therapy
  • Double-Blind Method
  • Humans
  • Interleukin-13 / blood*
  • Interleukin-5* / blood

Substances

  • Antibodies, Monoclonal, Humanized
  • IL13 protein, human
  • IL5 protein, human
  • Interleukin-13
  • Interleukin-5
  • tezepelumab

Associated data

  • ClinicalTrials.gov/NCT03688074